XERIJECT
Dead / Abandoned — Abandoned — no statement of use filed (as of 30 Sept 2024)
What this means for you
This application is over — abandoned 30 Sept 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90359515
- Mark type
- Stylized text
- Filed
- 04 Dec 2020
- Published for opposition
- 29 Jun 2021
- Abandoned
- 30 Sept 2024
- Attorney of record
- Tracy-Gene G. Durkin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of diseases and conditions, namely, alimentary tract, metabolic, oncologic, autoimmune, and nervous system diseases and conditions; pharmaceutical preparations for the treatment of diseases and conditions, namely, anti-invectives to prevent or treat infections, vaccines, antineoplastic pharmaceutical preparations for the treatment of cancer, and immunomodulating pharmaceutical preparations for the treatment of immune system related diseases and disorders
Owner
- Xeris Pharmaceuticals, Inc., Chicago, IL, US
- Xeris Pharmaceuticals, Inc., Chicago, IL, US
Prosecution history
- 30 Sept 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 30 Sept 2024 — ABANDONMENT - NO USE STATEMENT FILED
- 14 Feb 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Feb 2024 — SOU EXTENSION 5 GRANTED
- 13 Feb 2024 — SOU EXTENSION 5 FILED
- 13 Feb 2024 — SOU TEAS EXTENSION RECEIVED
- 13 Sept 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Sept 2023 — CORRECTED NOA E-MAILED
- 12 Sept 2023 — SOU EXTENSION 4 GRANTED
- 24 Aug 2023 — SOU EXTENSION 4 FILED
- 12 Sept 2023 — DIVISIONAL PROCESSING COMPLETE
- 24 Aug 2023 — DIVISIONAL REQUEST RECEIVED
- 30 Aug 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 24 Aug 2023 — TEAS REQUEST TO DIVIDE RECEIVED
- 24 Aug 2023 — SOU TEAS EXTENSION RECEIVED